Johnson & Johnson (J&J; NYSE: JNJ) has reported updates from a Phase I/II clinical trial for its bispecific antibody (BsAb) Tecvayli (teclistamab) in patients with relapsed or refractory multiple myeloma (r/rMM) who have received three or more prior lines of treatment. With a median follow-up of 30.4 months, the trial demonstrated overall and complete response rates of 63% and 46%, respectively. Additionally, the 30-month duration of response (DOR), progression-free survival (PFS), and overall survival (OS) rates were reported at 61%, 61%, and 74%, respectively.
Notably, high-risk subgroups showed response rates on par with the general study population.
As detailed in the company’s press release, Tecvayli, which targets CD3 and BCMA, has already received marketing authorization for the treatment of r/rMM in Europe.- Flcube.com
